US/UK/Canada

Share

Contacts

  • Cyxone AB
    Adelgatan 21 SE 211 22 Malmö
    +46 708882172
    +46 708882172
    http://www.cyxone.com

    • Quotes

    After thorough evaluation, we were able to decide upon this CRO as our partner of choice for these preclinical studies. The selected CRO has an excellent reputation and we got a great impression of their quality and professionalism from the start. We now look forward to take the next step in the development program for our Phase II candidate Rabeximod.
    Malin Berthold, Head of Project Management at Cyxone
    This market maker is now being implemented to increase liquidity of our stock, which has sometimes been low. We look very favorably on this support measure, which is primarily done to benefit our shareholders through reduced trading risks.
    Kjell G. Stenberg, CEO of Cyxone
    The acquisition of Rabeximod is the most important milestone since Cyxone was founded. I have been following Rabeximod's development in OxyPharma for a long time and believe that this investment is very beneficial for our shareholders. We have in a short time been able to build a world-class autoimmune product portfolio, which has permeated the discussions we have had with different stakeholders regarding the financing of Rabeximod's phase IIb study. This is why we are now taking the opportunity to complete the payment and hope to return soon to our shareholders with more positive news regarding Rabeximod.
    Kjell G. Stenberg, CEO of Cyxone
    Pick a time period -

    Cyxone assigns Aptuit for the capsulation of Phase II candidate Rabeximod

    Cyxone (publ), a Swedish biotech in autoimmune diseases, announced today that the company has signed an agreement with Aptuit, an Evotec company, to perform the capsulation of the Rabeximod substance. This is a key step in the preparation of the planned Phase IIb study, in which patients will be administered capsules with Rabeximod, therefore securing a further step in the Rabeximod Phase IIb program.Malin Berthold, Head of Project Management at Cyxone, comments “We are glad to enter this partnership with Aptuit. They were responsible for the successful capsulation for the previous 12-week

    Cyxone signs a UK contract research organization for six-month toxicology studies with Rabeximod

    Cyxone (publ), a Swedish biotech in autoimmune diseases, announced today that the company has signed an agreement with a UK contract research organization (CRO) to conduct the six-month toxicology studies with Rabeximod as required ahead of the Phase IIb study. Preparations for the toxicology studies began immediately with a plan of initiating the studies directly thereafter.Malin Berthold, Head of Project Management at Cyxone, comments “After thorough evaluation, we were able to decide upon this CRO as our partner of choice for these preclinical studies. The selected CRO has an excellent

    Correction: Interim Report January 1st to September 30th, 2019

    Report enclosed Summary of the interim reportFirst nine months (January 1st to September 30th, 2019) · Operating revenue KSEK 0 (0) · Income after financial items KSEK -14 894 (-10 893) · Earnings per share -0,40 (-0,55) · Cash and cash equivalents as of 30 September KSEK 12 307 (10 478) · Equity ratio as of 30 September 92,7 (90,7) % Third Quarter (July 1st to September 30th, 2019) · Operating revenue KSEK 0 (0) · Income after financial items KSEK -5 765 (-4 390) · Earnings per share -0,15 (-0,22) Significant events during the third quarter of 2019

    Interim Report January 1st to September 30th, 2019

    Summary of the interim reportFirst nine months (January 1st to September 30th, 2019) · Operating revenue KSEK 0 (0) · Income after financial items KSEK -14 894 (-10 893) · Earnings per share -0,40 (-0,55) · Cash and cash equivalents as of 30 September KSEK 12 307 (10 478) · Equity ratio as of 30 September 92,7 (90,7) % Third Quarter (July 1st to September 30th, 2019) · Operating revenue KSEK 0 (0) · Income after financial items KSEK -5 765 (-4 390) · Earnings per share -0,15 (-0,22) Significant events during the third quarter of 2019 · In July, an

    Kjell G. Stenberg steps down as CEO of Cyxone

    Cyxone (publ), a Swedish biotech in autoimmune diseases, announced today that the company's Board has resolved to find a new CEO to lead the company into its next phase. Kjell G. Stenberg has decided to step down from his position as CEO of the company immediately. Ola Skanung, CFO, will be acting as interim CEO. The recruitment process to find a new CEO begins immediately.Bert Junno, chairman of the Board at Cyxone, comments “The company is currently on the verge of entering a new stage of maturity being well-financed and having two clinical candidates. This is why we believe it is a good

    Cyxone announces that exercise of warrants TO3 amounted to 66% – is allocated 62.4 MSEK

    Cyxone (publ), a Swedish biotech in autoimmune diseases, today announced a positive outcome of the exercise of warrants of series 3 (TO3). A total of 11,622,863 warrants were exercised, corresponding to approximately 66 percent of all warrants, for subscription of 11,622,863 shares at a subscription price of 5.37 SEK per share. By the exercised warrants, Cyxone is thus allocated approximately 62.4 MSEK before issue costs.Last year, the company carried out a rights issue of units, consisting of a share and a warrant, with the subscription period October 8 to 23, 2018. The exercise period for

    Cyxone's CEO Kjell G. Stenberg increases holding in the company for private account

    Cyxone (publ), a Swedish biotech in autoimmune diseases, announced today that the company's CEO Kjell G. Stenberg has for private account increased his stake in the company by acquiring an additional 9,154 shares at a share price of 5.89 SEK.Kjell G. Stenberg, CEO of Cyxone, commented: “I recently returned from a successful partnering conference, Nordic Life Science Days, held this week in Malmö. It was great fun to meet several new contacts and update existing contacts with the latest progress we have made with the portfolio. Our candidates have great potential, which is why I choose to

    Cyxone’s chairman of the board Bert Junno expands his holding in the company and exercises warrants

    Cyxone (publ), a Swedish biotech in autoimmune diseases, announced today that the company’s chairman of the board Bert Junno increases his holding in Cyxone by exercise of 100 000 warrants.Bert Junno, chairman of the board for Cyxone, commented: “Cyxone is currently in a very eventful phase with several milestones on the horizon. The success that the candidates, T20K and Rabeximod, have been able to show so far has made me more convinced of the potential of Cyxone. I see a very bright future for the company, which is why I now choose to expand my private holdings.” Chairman of the board

    Cyxone’s CEO Kjell G. Stenberg expands his private holdings in the company

    Cyxone (publ), a Swedish biotech in autoimmune diseases, today announced that the company's CEO Kjell G. Stenberg has increased his private holdings in the company by acquiring 9,077 shares at a share price of 5.94 SEK.Kjell G. Stenberg, CEO of Cyxone, commented: “I have very strong belief in the projects and that our candidates may change the future treatments for MS and rheumatoid arthritis. I think this is just the beginning of our journey and I see this as a great opportunity for me to expand my personal holdings in the company at a good price.” CEO Kjell G. Stenberg also previously

    Mangold Insight publishes company analysis of Cyxone

    Cyxone (publ), a Swedish biotech in autoimmune diseases, today announced that an analysis of the company has been published by Mangold Insight.The company analysis was published on Tuesday, September 10, 2019. Mangold Insight has taken into account the company's potential for the next 12 months. The report can be read in its entirety in Swedish only on the company's website. ContactCyxone AB (publ)Kjell G. Stenberg, CEOTel: +46 (0) 723 816 168Email: kjell.g.stenberg@cyxone.comAdelgatan 21211 22 Malmö, Sweden About CyxoneCyxone AB is a clinical stage biotech company with

    First Berlin Equity Research publishes independent analysis of Cyxone

    Cyxone (publ), a Swedish biotech in autoimmune diseases, today announced that the internationally renowned research company First Berlin Equity Research has published an independent analysis report of Cyxone.The independent analysis covers the first half-year of 2019 and was published on Monday, December 04, 2018, where First Berlin Equity Research reviewed the company's potential with an expected but continued positive outcome. The report in English can be read in its entirety on the company's website. ContactCyxone AB (publ)Kjell G. Stenberg, CEOTel: +46 (0) 723 816 168Email:

    Cyxone explores orphan drug designation for Rabeximod

    Cyxone (publ), a Swedish biotechnology company in autoimmune diseases, today announced that the company's board of directors has decided to explore the possibilities of an orphan drug designation (ODD) of the drug candidate Rabeximod. An orphan drug status would mean that the drug candidate obtains a strengthened position under the Orphan Drug Act, as well as prevails under special regulatory frameworks designed to endorse development and shorten time to market. This is part of the continuous work to strengthen the control position of the company's own assets.Kjell G. Stenberg, CEO of

    Cyxone’s CEO Kjell G. Stenberg acquires additional shares in the company

    Cyxone (publ), a Swedish biotech in autoimmune diseases, today announced that the company’s CEO Kjell G. Stenberg has for private account increased his ownership in the company through the acquisition of additional share.Kjell G. Stenberg, CEO of Cyxone, commented: “Since Cyxone acquired Rabeximod and T20K, my knowledge of the projects has increased substantially with the data that has emerged and in conversations with clinics, our partners and others. Both T20K and Rabeximod are now in clinical development, the plans are set and, I believe that the company has a very good prospect to

    Interim Report January 1st to June 30th, 2019

    Summary of the interim reportFirst Half year (January 1st to June 30th, 2019) · Operating revenue KSEK 0 (0) · Income after financial items KSEK -9 129 (-6 503) · Earnings per share -0,24 (-0,37) · Cash and cash equivalents as of 30 June KSEK 23 872 (17 817) · Equity ratio as of June 30th 94,3 (92,8) % Second Quarter (April 1st to June 30th, 2019) · Operating revenue KSEK 0 (0) · Income after financial items KSEK -4 366 (-3 755) · Earnings per share -0,12 (-0,21) Significant events during the second quarter of 2019 · In May, the registration of Cyxone

    Cyxone strengthens team ahead of continued development of T20K and Rabeximod

    Cyxone (publ.), a Swedish biotech in autoimmune diseases, today announced that the company is expanding its team with Malin Berthold as project manager for the next step in the development of Cyxone's clinical drug portfolio. Malin will primarily lead and coordinate the preclinical and clinical development programs in the company. She will be the company's primary contact with external key partners such as CROs, toxicology laboratories, pharmaceutical manufacturers, formulation experts, analysis laboratories and communication experts. Further responsibility is to regularly report the

    Cyxone’s T20K shows favorable safety and tolerability in first-in-human trial

    Cyxone (publ), a Swedish biotech in autoimmune diseases, today announced that the clinical phase I trial with drug candidate T20K successfully achieved its purpose of confirming T20K’s safety and tolerability in humans. There were no reports of serious adverse events in this infusion study. T20K, which is under development for the treatment of multiple sclerosis (MS), will as a next step in the development program be prepared as an oral formulation followed by a further clinical phase I study.The first-in-human study, so-called clinical phase I trial, achieved its objective of determining

    Cyxone makes further strides with Rabeximod phase IIb trial by signing CRO EGeen Inc.

    Cyxone (publ), a Swedish biotech in autoimmune diseases, today announced that the company has signed an agreement with EGeen Inc., a clinical research organization (CRO), for conducting its upcoming clinical phase IIb trial with Rabeximod in rheumatoid arthritis (RA) in select Eastern European countries. Cyxone is now, together with several partners, finalizing the necessary applications for permission to run its phase IIb multicenter study in both Western and Eastern Europe. The first application has been submitted and the remaining, up to eight, applications are expected to be submitted

    Cyxone announce dosing of first volunteer in T20K’s first-in-human trial

    Cyxone (publ.) a Swedish biotech in autoimmune diseases, today announced that the first healthy male volunteer has received the initial dose in its first-in-human, clinical phase I, trial with drug candidate T20K, in development for the treatment of multiple sclerosis (MS). The clinical phase I study is estimated to be concluded during the second half of 2019.The recruitment and screening of healthy male volunteers for Cyxone’s first-in-human trial with T20K was initiated in June of this year, following the approval from the relevant authorities in the Netherlands where the study site is

    Cyxone submits first application to start clinical phase IIb trial with Rabeximod

    Cyxone (publ), a Swedish biotech in autoimmune diseases, today submitted an application to the Central Ethics Committee (CEC) in Poland for permission to start a clinical phase IIb trial with its drug candidate Rabeximod, which is in development for the treatment of rheumatoid arthritis (RA). This first application will be followed by an application to the Competent Authority in Poland during the third quarter of 2019, and subsequently, by applications to the relevant regulatory authorities in additional European countries. The multi-center clinical phase IIb trial with Rabeximod in RA is

    First Berlin Equity Research publishes updated independent analysis of Cyxone

    Cyxone (publ) announced today that the internationally renowned research company First Berlin Equity Research has published an updated independent analysis report of Cyxone.The updated analysis was published on Monday, July 01, 2019, where First Berlin Equity Research has further taken into account the company's potential with a continued positive outcome. The report in English can be read in its entirety on the company's website. ContactCyxone AB (publ)Kjell G. Stenberg, CEOTel: +46 (0) 723 816 168Email: kjell.g.stenberg@cyxone.comAdelgatan 21211 22 MalmöSweden About

    Cyxone initiates first-in-human trial with T20K for the treatment of MS

    Cyxone (publ.), a Swedish biotech in autoimmune diseases, today announced that the company starts its first-in-human, phase I, clinical trial with drug candidate T20K for the treatment of multiple sclerosis (MS) immediately following the authorities’ approval. Currently, the focus is the recruitment and screening of healthy male volunteers for the study.Cyxone’s application to start a first-in-human, phase I, trial with their prophylactic drug candidate T20K targeting multiple sclerosis (MS) has been approved by the accredited Ethics Committee and Central Commission on Research Involving

    Cyxone submits application to start first-in-human trial with T20K in MS

    Cyxone (publ.), a Swedish biotech in autoimmune diseases, today announced that the company has set a date for the application submission for the start of clinical trials with T20K. On Monday May 27, an application to the relevant authorities to start a first-in-human, phase I, clinical trial with drug candidate T20K in multiple sclerosis (MS) will be submitted. The company will subsequently await a response from the authorities before the study can be initiated as planned during the second quarter of 2019.The application to start the first-in-human clinical trial for T20K in MS will on

    Cyxone forms a subsidiary in Switzerland

    Cyxone (publ), a Swedish biotech in autoimmune diseases, today announced that the company has initiated registration of Cyxone Switzerland AG, a wholly-owned subsidiary in Switzerland. The subsidiary, which is to be located in Basel, is an important step in strengthening the company’s global presence and opens up for a wider reach of international investments and collaborations.Kjell G. Stenberg, CEO of Cyxone, commented: “Establishing Cyxone Switzerland AG gives a clear signal of Cyxone’s future growth ambitions. Switzerland is the home of a number of well-established life science and Big

    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe